The potential implications of ER-positive and ER-negative statuses in the context of BRCA-mutated ovarian cancer and how these interactions might impact treatment outcomes should be further investigated, as the available data are not as strong, as in the case of breast cancer (where ER-positive BRCA-mutated breast cancer is a special subgroup of patients with poor prognosis). The gene discussed is ESR1; the disease is ovarian cancer.